STUDIES ON FORMULATION DEVELOPMENT AND IN VITRO EVALUATION OF CELECOXIB MATRIX TABLET CONTAINING COMBINATION OF EQUAL RATIO OF NATURAL GUMS GUARGUM AND CYCLODEXTRIN, AMYLOSE AND PECTIN FOR COLON SPECIFIC DRUG DELIVERY
AbstractBackdrop: The design, development, formulation and in vitro evaluation of colon targeted drug delivery system with natural polysaccharides was studied with Guargum, Cyclodextrin, Amylose and Pectin. Hence it motivated us to find the combined effect of the natural polysaccharides with Celecoxib matrix tablet for specific targeting to colon. Process: Celecoxib matrix tablet was prepared by drug with equal ratio of Guargum+Cyclodextrin(A+B), Amylose+Pectin (C+D) were taken in the following equal ratio 1:0.2, 1:0.3 & 1:0.4 ratio of both gums, 2% of starch paste was added as binder. The micro crystalline cellulose was added to make the tablet total weight of 200mg.The formulations were coded as (A+B) EF1, (A+B) EF2, (A+B) EF3, (C+D) FF1, (C+D) FF2 and (C+D) FF3respectively. The preformulation studies such as Bulk density (g/cm3), Tapped density (g/cm3), Compressibility index (%), Angle of repose, Average particle size (µm) were determined. Outcome: The formulated Celecoxib Matrix tablet was evaluated for its hardness, friability, weight variation, thickness and diameter. The discharge summary of the matrix tablet was carried out in Simulated Gastric Fluid (SGF), Simulated Intestinal Fluid (SIF), Simulated Colonic Fluid(SCF). The in vitro release profile of Celecoxib matrix tablet (A+B), (C+D) was found to be (EF2)88.4%, (FF2)95.3% correspondingly. Ending: It was found 1.5%, 6% of drug release was observed at 2 hrs, 4-8 hrs respectively with Simulated Gastric fluid and maximum of 95.3% of drug release was found after 24 hours of dissolution study. The above study suggests combined effect of amylose & pectin gives ceiling release for specific colon targeting especially for colon cancer.
Article Information
39
5273-78
358
1454
English
IJPSR
P. Arulraj *, V. Gopal, G. Jeyabalan, C. S. Kandasamy, Sam Johnson J. Udaya Chander and R. Venkatanarayanan
Department of Pharmaceutical Biotechnology, RVS College of Pharmaceutical Sciences, Coimbatore, Tamil Nadu, India
arulraj.p@rvsgroup.com
11 June, 2015
27 July, 2015
03 October, 2015
10.13040/IJPSR.0975-8232.6(12).5273-78
01 December, 2015